# Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

> **NCT06614270** · NA · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 15 (estimated)

## Conditions studied

- Systemic Sclerosis (SSc)
- ANCA Associated Vasculitis (AAV)
- Idiopathic Inflammatory Myopathy (IIM)
- Sjogren's Syndrome
- Antiphospholipid Syndrome
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Anti-CD19 IL-10/IL15 CAR-NK

## Key facts

- **NCT ID:** NCT06614270
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-06
- **Primary completion:** 2026-01-06
- **Final completion:** 2027-01-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614270, "Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06614270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*